Article Details

DEVELOPMENT AND VALIDATION OF RP-HPLC-PDA METHOD FOR THE ESTIMATION OF SARPOGRELATE HYDROCHLORIDE IN BULK AND DOSAGE FORMS

Vijaya Lakshmi M.*, Hima Bindu K., Pravallika M. and Nalluri B. N.

Department of Pharmaceutical Analysis, K.V.S.R. Siddhartha College of Pharmaceutical Sciences, Vijayawada - 520 010, Andhra Pradesh, India.

*For correspondence: E-mail: analysis.scops@gmail.com

 

https://doi.org/10.53879/id.55.04.10915


ABSTRACT

A simple and precise RP-HPLC method has been developed and validated for the estimation of sarpogrelate hydrochloride, an anti-platelet drug in bulk and pharmaceutical dosage forms. Sarpogrelate is an antagonist at 5HT2A and 5HT2B receptors which blocks serotonin induced platelet aggregation and has application in the treatment of diseases including diabetes mellitus, Raynaud’s disease, angina pectoris and atherosclerosis. Chromatography was carried out on a Phenomenex C18 (250 x 4.6mm, 5μm) column with a mobile phase of 10mM ammonium acetate and acetonitrile (45:55% v/v). The flow rate was 1.2mL/min. The detection wavelength was carried out at 220nm. The retention time is 3.356 minutes for sarpogrelate hydrochloride. The linearity was found in the range of 10-50 μg/ml (R = 0.999) and % RSD is less than 2%. The mean recoveries obtained for sarpogrelate hydrochloride were in the range of 98.73-100.67%. The method is validated as per ICH guidelines and can be applied for the estimation of percentage purity in Sarpogrelate hydrochloride for quality control analysis in bulk and its dosage forms.

Year 2018 | Volume No. 55 | Issue No.04 | Page No. 77-80
Recent Issue
Current Issue
May 2024
Quick Contact